Alligator Bioscience and Aptevo today announced further details of the companies’ collaboration on ALG.APV-526, a bispecific antibody targeting 4-1BB and a tumor antigen, now identified as 5T4, which is found on various types of cancer cells.
ALG.APV-527 - A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications. |
| [24-October-2017] |
| LUND, Sweden and SEATTLE, Washington, October 24, 2017 /PRNewswire/ -- Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced further details of the companies’ collaboration on ALG.APV-526, a bispecific antibody targeting 4-1BB and a tumor antigen, now identified as 5T4, which is found on various types of cancer cells. 5T4 is a protein predominantly expressed on tumor cells. It is present at very low levels or not at all in normal tissue. This enables the immune-activating effect of ALG.APV-527 to be targeted specifically to the tumor and not against normal tissue, the goal being effective tumor-directed immune activation with minimal side effects. The 5T4 tumor antigen is present on a number of different solid tumors, including breast, cervical, non-small-cell-lung, prostate, renal, gastric, colorectal and bladder cancers, indicating that ALG.APV-527 may be used for the treatment of several different types of cancer. “The fact that 5T4 is selectively expressed on tumor cells in many different cancer indications, but in very low levels in normal tissue, makes it a very attractive target for tumor-directed immunotherapy,” said Professor Peter Stern, Manchester University, UK. By combining a tumor-binding and an immunomodulatory antibody in one molecule, Alligator and Aptevo have created a drug candidate whose effect is localized to the tumor area, activating the tumor-specific immune cells present there. About Dr. Peter Stern About ALG.APV-527 About Aptevo Therapeutics Inc. About Alligator Bioscience Safe Harbor Statement for Aptevo There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the closing of the transaction;; a deterioration in Aptevo’s business or prospects; the parties may be unable to achieve the anticipated benefits of the transaction; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 31, 2017, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo’s expectations in any forward-looking statement. For Further Information: This release contains information that Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 3:00 p.m. CEST on 24 October 2017. Aptevo Therapeutics This information was brought to you by Cision http://news.cision.com The following files are available for download: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV- http://mb.cision.com/Main/12681/2374405/740886.pdf 527
SOURCE Alligator Bioscience | ||
Company Codes: Bloomberg:ATORX@SS, ISIN:SE0000767188, RICS:ATORX.ST, Stockholm:ATORX |
